Predictors of Success of IUI in Unexplained Infertility

Factors Affecting Success of IUI in Women With Unexplained Infertility

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02787811

Enrollment

100

Registered

2016-06-01

Start date

2016-05-31

Completion date

2017-02-28

Last updated

2017-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Assisted Reproductive Techniques

Keywords

IUI, Pregnancy rate, predictors

Brief summary

Superovulation will be conducted with 100 mg of oral clomiphene citrate (Clomifene; Young Poong Pharmaceutical, Incheon, Korea) for 5 days starting on day 3 of the menstrual cycle, followed by daily injection of 150 IU of human menopausal gonadotropin (hMG;Menogon; FerringPharamceutical Co, Germany). When more than 2 dominant follicles reached a diameter of 17 mm or the urinary specimen showed positive results for luteinizing hormone (LH) surge, 5000 IU of hCG (Pregnyl; Organon, Oss, the Netherlands) was injected intramuscularly.

Detailed description

Superovulation will conducted with 100 mg of oral clomiphene citrate (Clomifene; Young Poong Pharmaceutical, Incheon, Korea) for 5 days starting on day 3 of the menstrual cycle, followed by daily injection of 150 IU of human menopausal gonadotropin (hMG;Menogon; FerringPharamceutical Co, Germany). When more than 2 dominant follicles reached a diameter of 17 mm or the urinary specimen showed positive results for luteinizing hormone (LH) surge, 5000 IU of hCG (Pregnyl; Organon, Oss, the Netherlands) was injected intramuscularly. Successful pregnancy after IUI was confirmed by ultrasound as one or more visible gestational sacs in the uterine cavity.

Interventions

DEVICEIntrauterine insemenation

Semen preparation processing hen intrauterine transfer after 24 hours of HCG triggering of ovulation

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 40 Years

Healthy volunteers

Inclusion criteria

* These patients had at least 1 tube patent * there were no significant intrauterine or pelvic abnormalities demonstrated on pelvic-abdominal ultrasonography, hysteroscopy, and/or laparoscopy * serum follicular stimulating hormone (FSH) level of12 mIU/mL or less

Exclusion criteria

* A woman's age of more than 40 years, * ovarian cyst detected in the ultrasound examination * uterine lesions such as submucosal leiomyoma, and a previous diagnosis of moderate to severe pelvic endometriosis. * women with body mass index \> 35 kg/m2, * PCOS/anovulatory patients * signs of hyperandrogenemia

Design outcomes

Primary

Measure	Time frame
chemical pregnancy rate	14 days after IUI

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026